A Phase 1/2 interventional study of Mild Intermittent Hypoxia and Sham MIH in Obstructive Sleep Apnea, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by VA Office of Research and Development · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development — 7 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · VA Office of Research and Development.
Among the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development, this one is the 13th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 1/2, and was the 21st registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →7 of the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages up to 65
VA Office of Research and Development · Sites in United States
Ages 40–65
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 60+
By country, each count listing its studies:
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 92 across the 22 interventional studies, 3,351 across the 2 observational. Of the 16 that completed or were terminated, 14 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
7 of the studies in Sleep Apnea, Obstructive by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02703207VA Office of Research and DevelopmentNeurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD | 2026-12-31 |
| NCT06291870VA Office of Research and DevelopmentPredictors of Post-COVID-19 Clinical and Cognitive Consequences | 2026-12-31 |
| NCT05558501VA Office of Research and DevelopmentIntermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities | 2026-12-31 |
| NCT06477952VA Office of Research and DevelopmentDRonabinol Treatment of OSA | 2027-03-31 |
| NCT05156112VA Office of Research and DevelopmentOSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prevalence of obstructive sleep apnea (OSA) is high in the United States and is a major health concern. This disorder is linked to numerous heart, blood vessel and nervous system abnormalities, along with increased tiredness while performing exercise likely because of a reduced blood supply to skeletal muscles. The gold standard treatment of OSA with continuous positive airway pressure (CPAP) in many cases does not lead to significant improvements in health outcomes because the recommended number of hours of treatment per night is often not achieved. Thus, development of novel treatments to eliminate apnea and lessen the occurrence of associated health conditions is important. The investigators will address this mandate by determining if repeated exposure to mild intermittent hypoxia (MIH) reduces heart and blood vessel dysfunction and tiredness/ fatigue experienced while exercise performance. The investigators propose that exposure to MIH has a multipart effect. MIH directly targets heart and blood vessel associated conditions, while simultaneously increasing upper airway stability and improving sleep quality. These modifications may serve to directly decrease breathing episodes and may also serve to improve usage of CPAP. Independent of its effect, MIH may serve as an adjunctive therapy which provides another path to reducing heart and blood vessel abnormalities that might ultimately result in improvements in exercise capacity and reverse performance fatigue in individuals with OSA.
The prevalence of obstructive sleep apnea (OSA) is high in the Veteran population and this disorder is linked to numerous cardiovascular, neurocognitive and metabolic abnormalities. Thus, OSA is a major health concern in the Veteran population. Treatment of OSA in many cases does not lead to significant improvements in outcome measures. This inadequacy may be a consequence of reduced treatment adherence with continuous positive airway pressure (CPAP) or because the effect of CPAP on outcome measures is small or absent in some patients despite adequate adherence. Consequently, innovative therapies that directly impact co-morbidities linked to OSA or that increase CPAP adherence could lead to improved outcome measures. In the recent funding cycle, the investigators established that repeated daily exposure to mild intermittent hypoxia (MIH) coupled with CPAP modifies autonomic nervous system activity and dramatically decreases blood pressure compared to CPAP treatment alone. Because MIH was coupled with CPAP, the independent effect of MIH on blood pressure was not established. Moreover, it was not established if these outcomes were sustained for a prolonged time period (i.e. weeks to months).
Although the investigators obtained some indirect evidence that modifications in autonomic nervous system activity were coupled to the reduction in blood pressure, the investigators did not establish if modifications in microvascular function were evident. Microvascular dysfunction together with sympatho-vagal imbalance may have consequences not only for peripheral vascular resistance and blood pressure but also for muscle perfusion and metabolism, thereby limiting exercise performance and increasing fatigability in patients with OSA. Thus, reductions in blood pressure and improvement in microvascular function following treatment with MIH might serve to improve exercise capacity and reverse performance fatigue in individuals with OSA.
Besides its potential effect on autonomic and cardiovascular function, the investigators and others previously established that acute exposure to MIH initiates sustained increases in upper airway muscle activity in humans. This sustained increase is a form of respiratory plasticity known as long-term facilitation. However, in the absence of CPAP the investigators have shown that acute MIH immediately prior to or during sleep leads to increases in apnea severity. This might occur because the manifestation of long-term facilitation is absent in the presence of hypocapnia. Hypocapnia can be induced during sleep by the initiation of another form of plasticity known as progressive augmentation. However, it is possible that the combination of daily exposure to MIH administered many hours before the sleep period may mitigate the effects of progressive augmentation leading to increased upper airway stability.
Independent of this possibility, the investigators showed in the previous funding cycle that increased upper airway stability following treatment with MIH was coupled to a reduction in therapeutic CPAP and improved adherence. However, improved adherence to CPAP might also be linked to an increase in the arousal threshold to both respiratory and non-respiratory stimuli. All the uncertainties outlined above will be addressed in the present proposal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm of the protocol will receive mild intermittent hypoxia (8% oxygen) with end-tidal carbon dioxide maintained 2 millimeters of mercury above baseline, while in the laboratory.
Other: Mild Intermittent Hypoxia
This arm of the protocol will receive sham MIH (the equivalent of room air), while in the laboratory.
Other: Sham MIH
The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2)= 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
During "sham MIH" the participants will be exposed to compressed air (the equivalent of room air).
Change in Blood Pressure
Blood pressure measures over 24 hours will be obtained. Blood pressure will be measured every 20 minutes beginning on Sunday at 6 AM and ending Monday at 6 AM. Participants will wear an actigraph (Actiwatch Spectrum, Respironics) and record their activities in a journal to determine the arousal state (i.e., active wakefulness, quiet wakefulness and sleep) associated with each blood pressure measurement. The data will be separated into active-awake, rest-awake and sleep based on the activity log and corresponding data from an actigraph watch. The average value of blood pressure in a healthy individual is 120/80 mmHg. In their participants with OSA, the investigators expect the blood pressure to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Microvascular Function (Maximal hyperemic Response)
Microvascular reactivity associated with hyperemia induced by vascular occlusion will be determined by analyzing the maximal hyperemic response (MHR) of tissue saturation index (TSI) signal derived from near-infrared spectroscopy (NIRS) of the lateral gastrocnemius muscle of the non-dominant leg. The average value of TSI MHR of the NIRS signals in healthy individuals is 159±9 %. In their participants with OSA, the investigators expect these values to be lower at baseline and to increase 15 days after treatment. The investigators also expect that the increase will be maintained 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Microvascular Function (Time to reach Maximal Hyperemic Response)
Microvascular reactivity associated with hyperemia induced by vascular occlusion will be determined by analyzing the time to reach maximal hyperemic response (tM) of tissue saturation index (TSI) signal derived from near-infrared spectroscopy (NIRS) of the lateral gastrocnemius muscle of the non-dominant leg. The average value of tM TSI in healthy individuals is 39±5 s. In their participants with OSA, the investigators expect these values to be higher at baseline and to lower 15 days after treatment. The investigators also expect that the decrease will be maintained 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Muscle Oxygen Extraction (Time Delay)
Gastrocnemius muscle deoxygenation will be determined by monitoring temporal variables i.e. time delay of \[HHb\] signal recorded during the MIH and "sham MIH" treatment. Lying in a supine position, participants will be fitted with the NIRS optode on the belly of the lateral gastrocnemius muscle secured with a double tape or a velcro strap. The NIRS data will be recorded continuously at a sampling rate of 10 Hz and will be analyzed off line. The average reported value of \[HHb\] time delay in a healthy individual is 14.8±1.6s. In their participants with OSA, the investigators expect these values to be higher at baseline and decrease 15 days after treatment.
Time frame: Change at 15 days following treatment compared to baseline
Change in Muscle Oxygen Extraction (Mean Response Time)
Gastrocnemius muscle deoxygenation will be determined by monitoring temporal variables i.e. mean response time of \[HHb\] signal recorded during the MIH and "sham MIH" treatment. Lying in a supine position, participants will be fitted with the NIRS optode on the belly of the lateral gastrocnemius muscle secured with a double tape or a velcro strap. The NIRS data will be recorded continuously at a sampling rate of 10 Hz and will be analyzed off line. The average reported value of \[HHb\] mean response time in a healthy individual is 27.2±2.9s. In their participants with OSA, the investigators expect these values to be higher at baseline and decrease 15 days after treatment.
Time frame: Change at 15 days following treatment compared to baseline
Change in Sympatho-Vagal Balance (Blood Pressure Variability)
Blood pressure variability will be assessed non-invasively using beat to beat measures of blood pressure. The ratio of low frequency and high frequency range (LF-HF ratio) obtained from the power spectrum analysis of blood pressure variability is considered representative of sympathetic to parasympathetic balance in both physiological and pathophysiological conditions. The normal range of LF-HF ratio in a healthy individual is 1.5-2. In their participants with OSA, the investigators expect the ratio to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Muscle Oxygen Extraction (Tau)
Gastrocnemius muscle deoxygenation will be determined by monitoring temporal variable i.e. tau of \[HHb\] signal recorded during the MIH and "sham MIH" treatment. Lying in a supine position, participants will be fitted with the NIRS optode on the belly of the lateral gastrocnemius muscle secured with a double tape or a velcro strap. The NIRS data will be recorded continuously at a sampling rate of 10 Hz and will be analyzed off line. The average reported value of \[HHb\] tau in a healthy individual is 12.4±2.2s. In their participants with OSA, the investigators expect these values to be higher at baseline and decrease 15 days after treatment.
Time frame: Change at 15 days following treatment compared to baseline
Change in Maximal Oxygen Consumption
All the participants will complete a maximum oxygen consumption (VO2 max) test using a treadmill. Continuous monitoring of electrical activity of the heart with an electrocardiogram along with the measurement of breath by breath oxygen consumption and carbon dioxide production will be performed. The average value of VO2 max in a healthy individual is 35-40 mL/kg/min. In their participants with OSA, the investigators expect the maximal oxygen consumption to be lower at baseline and increase 15 days after treatment. The investigators also expect that this increase will be maintained at 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Fatigability
Participants will perform a 10-minute walk test on a 25 m indoor walking course at the beginning and end of the protocol. The distance covered will be recorded every 2.5 minutes and at the end of 10 minutes. The ratio of the average walking speed calculated over the entire 10 minutes of walking and the walking velocity calculated over the first 2.5 minutes of the test will be computed. This ratio will then be normalized to the total distance covered in 10 minutes to calculate the performance fatigability index. The average value of performance fatigability index in a healthy individual is less than 1. In the participants with OSA, the investigators expect the performance fatigability index to be higher at baseline and reduce 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Sympatho-Vagal Balance (Heart Rate Variability)
Heart rate variability will be assessed non-invasively using beat to beat measures of heart rate. The ratio of low frequency and high frequency range (LF-HF ratio) obtained from the power spectrum analysis of heart rate variability is considered representative of sympathetic to parasympathetic balance in both physiological and pathophysiological conditions. The average value of LF-HF ratio in a healthy individual is 1.6±1. In their participants with OSA, the investigators expect the ratio to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in CPAP Adherence
CPAP adherence will be assessed by documenting the number of hours of CPAP used per night. The average value of CPAP adherence in an individual with OSA is 3.92±0.65 hours per night. In our participants with OSA, the investigators expect the ratio to be lower at baseline and increase 15 days after treatment. The investigators also expect that this increase will be maintained 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8-weeks following treatment compared to baseline
Change in Arousal Threshold
Arousal threshold to respiratory and non-respiratory (tactile and auditory) stimuli will be measured during baseline polysomnographic and CPAP titration night studies. The average value of tone-induced arousal threshold in an individual with OSA is 64.5±2.2 dB. In our participants with OSA, the investigators expect the dB level to be lower at baseline and increase 15 days after treatment. The investigators also expect that this increase will be maintained at 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Sleep Apnea Severity
Sleep apnea severity will be determined from the apnea hypopnea index obtained from overnight polysomnographic studies. The average value of the apnea hypopnea index in a healthy individual is less than 5 events per hour. In our participants with OSA, we expect the index to be higher at baseline and decrease 15 days after treatment. We also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Time frame: Change at 15 days, 4 and 8-weeks following treatment compared to baseline
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →